Evidence map›Paper›PMID 29338381›Full record

ArticleCell transplantation2017

Effect of the Diabetic State on Islet Engraftment and Function in a Large Animal Model of Islet-Kidney Transplantation.

Prashanth Vallabhajosyula, Atsushi Hirakata, Matthew Weiss, Adam Griesemer, Akira Shimizu, Hanzhou Hong, Andreas Habertheuer, Vaja Tchipashvili, Kazuhiko Yamada, David H Sachs

Open access · goldAbstract read
In one paragraph

Article in Cell transplantation, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Prashanth Vallabhajosyula1 Transplantation Biology Research Center, Massachusetts General Hospital, Boston, MA, USA.
Atsushi Hirakata1 Transplantation Biology Research Center, Massachusetts General Hospital, Boston, MA, USA.
Matthew Weiss1 Transplantation Biology Research Center, Massachusetts General Hospital, Boston, MA, USA.
Adam Griesemer1 Transplantation Biology Research Center, Massachusetts General Hospital, Boston, MA, USA.
Akira Shimizu1 Transplantation Biology Research Center, Massachusetts General Hospital, Boston, MA, USA.
Hanzhou Hong1 Transplantation Biology Research Center, Massachusetts General Hospital, Boston, MA, USA.
Andreas Habertheuer2 Division of Cardiovascular Surgery, Department of Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
Vaja Tchipashvili3 Department of Islet Transplantation and Cell Biology, Joslin Diabetes Center, Boston, MA, USA.
Kazuhiko Yamada1 Transplantation Biology Research Center, Massachusetts General Hospital, Boston, MA, USA.
David H Sachs1 Transplantation Biology Research Center, Massachusetts General Hospital, Boston, MA, USA.
Massachusetts General Hospital · USHospital of the University of Pennsylvania · USJoslin Diabetes Center · US

Funding

Tolerance to Vascularized Allografts in MiniswineR56AI031046 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI SACHS, DAVID H · 2017 to 2017
$733k
NIAID NIH HHS R56 AI031046
6 · The paper itself

Abstract

In islet transplantation, in addition to immunologic and ischemic factors, the diabetic/hyperglycemic state of the recipient has been proposed, although not yet validated, as a possible cause of islet toxicity, contributing to islet loss during the engraftment period. Using a miniature swine model of islet transplantation, we have now assessed the effect of a persistent state of hyperglycemia on islet engraftment and subsequent function. An islet-kidney (IK) model previously described by our laboratory was utilized. Three experimental donor animals underwent total pancreatectomy and autologous islet transplantation underneath the renal capsule to prepare an IK at a load of ≤1,000 islet equivalents (IE)/kg donor weight, leading to a chronic diabetic state during the engraftment period (fasting blood glucose >250 mg/dL). Three control donor animals underwent partial pancreatectomy (sufficient to maintain normoglycemia during islet engraftment period) and IK preparation. As in vivo functional readout for islet engraftment, the IKs were transplanted across an immunologic minor or class I mismatch barrier into diabetic, nephrectomized recipients at an islet load of ∼4,500 IE/kg recipient weight. A 12-d course of cyclosporine was administered for tolerance induction. All experimental donors became diabetic and showed signs of end organ injury, while control donors maintained normoglycemia. All recipients of IK from both experimental and control donors achieved glycemic control over long-term follow-up, with reversal of diabetic nephropathy and with similar glucose tolerance tests. In this preclinical, large animal model, neither islet engraftment nor subsequent long-term islet function after transplantation appear to be affected by the diabetic state.

Indexed as

AnimalsBlood GlucoseGlucose Tolerance TestHyperglycemiaIslets of Langerhans TransplantationKidney TransplantationPancreatectomySwineSwine, MiniatureBlood Glucosehyperglycemiaislet–kidneyislet transplantpig

Identifiers

PMID29338381
PMCPMC5784526
OpenAlexW2792966197

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.